湖南依微迪医疗器械有限公司 审计报告及财务报表 二○二五年一至三月 湖南依微迪医疗器械有限公司 审计报告及财务报表 （2025 年 01 月 01 日至 2025 年 3 月 31 日止） | | | 目录 | 页次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-3 | | 二、 | 财务报表 | | | | | 资产负债表 | | 1-2 | | | 利润表 | | 3 | | | 现金流量表 | | 4 | | | 所有者权益变动表 | | 5-6 | | | 财务报表附注 | | 1-45 | 审计报告 信会师报字[2025]第 ZA14660 号 湖南依微迪医疗器械有限公司全体股东： 一、 审计意见 我们审计了湖南依微迪医疗器械有限公司（以下简称依微迪）财 务报表，包括 2025 年 3 月 31 日的资产负债表，2025 年 1-3 月的利润 表、现金流量表、所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了依微迪 2025 年 3 月 31 日的财务状况以及 2025 年 1-3 月的 ...

北京市嘉源律师事务所 关于深圳惠泰医疗器械股份有限公司 2021 年限制性股票激励计划 授予价格、授予及归属数量调整相关事项的 法律意见书 名所 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 源律师事务所 YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:深圳惠泰医疗器械股份有限公司 北京市嘉源律师事务所 关于深圳惠泰医疗器械股份有限公司 2021 年限制性股票激励计划 授予价格、授予及归属数量调整相关事项的法律意见书 嘉源(2025)-05-236 敬启者: 北京市嘉源律师事务所(以下简称"本所")接受深圳惠泰医疗器械股份有 限公司(以下简称"惠泰医疗"或"公司")的委托,担任惠泰医疗实施2021年 限制性股票激励计划(以下简称"本激励计划")的专项法律顾问,就本激励计 划的相关事项出具法律意见书。 本法律意见书系依据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股权激励管 ...

深圳惠泰医疗器械股份有限公司 章 程 二〇二五年七月 | 第一章 | 总则 2 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 4 | | | 第一节 | 股份发行 | 4 | | 第二节 | 股份增减和回购 | 5 | | 第三节 | 股份转让 | 7 | | 第四章 | 股东和股东会 | 7 | | 第一节 | 股东的一般规定 | 7 | | 第二节 | 控股股东和实际控制人 | 10 | | 第三节 | 股东会的一般规定 | 11 | | 第四节 | 股东会的召集 | 15 | | 第五节 | 股东会的提案与通知 | 17 | | 第六节 | 股东会的召开 | 18 | | 第七节 | 股东会的表决和决议 | 21 | | 第五章 | 董事会 26 | | | 第一节 | 董事 26 | | | 第二节 | 董事会 | 31 | | 第三节 | 独立董事 | 36 | | 第四节 | 董事会专门委员会 | 39 | | 第六章 | 高级管理人员 | 41 | | 第七章 | 财务会计制度、利润分配和审计 | 44 | | 第一节 | 财务 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-033 深圳惠泰医疗器械股份有限公司 关于变更注册资本暨修订《公司章程》的公告 上述变更最终以工商登记机关核准的内容为准。除上述修订条款外，《公司 章程》其他条款保持不变。修订后的《公司章程》全文将同日披露于上海证券交 易所网站(www.sse.com.cn)。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日 召开了第二届董事会第二十三次会议，审议通过了《关于变更注册资本暨修订< 公司章程>的议案》。具体情况如下： 一、注册资本变更情况 公司于 2025 年 5 月 13 日召开了 2024 年年度股东大会，审议通过了《关于 公司<2024 年度利润分配及资本公积金转增股本预案>的议案》，同意公司以实 施权益分派股权登记日登记的股份总数为基数，向全体股东按每 10 股派发现金 红利人民币 17.50 元（含税），以资本公积金向全体股东每 10 股转增 4.5 股，不 送红股。本次 ...

深圳惠泰医疗器械股份有限公司 证券代码：688617 证券简称：惠泰医疗 公告编号：2025-034 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易简要内容 湖南依微迪医疗器械有限公司（以下简称"依微迪"）系深圳惠泰医疗器械 股份有限公司（以下简称"公司"或"惠泰医疗"）的控股子公司，公司直接持 有依微迪 42.3380%的股权，并通过公司控制的上海惠泰中赛私募投资基金合伙 企业（有限合伙）（以下简称"惠泰中赛基金"）合计控制依微迪 68.9512%的 股权。 依微迪股东周义超拟将其合计持有的 10.0000%依微迪股权以人民币 1,300.0000 万元的价格转让给上海惠启迪企业管理中心（有限合伙）（以下简称 "上海惠启迪"）、惠泰医疗、上海惠深创业投资中心（有限合伙）（以下简称 "上海惠深"）；蒋真拟将其持有的 4.5464%依微迪股权以人民币 591.0354 万元 的价格转让给刘慕竹；姜兰拟将其合计持有的 4.5464%依微迪股权以人民币 591.0355 万元的价格转让给上海惠深、上海惠圳创 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-031 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《深 圳惠泰医疗器械股份有限公司关于公司放弃部分优先购买权、向控股子公司增资 构成与关联方共同投资暨关联交易的公告》（公告编号：2025-034）。 本议案已经公司第二届董事会审计委员会第十四次会议、第二届董事会战略 与投资委员会第五次会议、2025 年第二次独立董事专门会议审议通过。 本议案尚需提交公司股东会审议。 董事会表决结果：7 票同意，反对 0 票，弃权 0 票。关联董事成正辉、戴振 华回避表决。 二、审议通过《关于调整 2021 年限制性股票激励计划授予价格、授予及归 属数量的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《深 圳惠泰医疗器械股份有限公司关于调整 2021 年限制性股票激励计划授予价格、 授予及归属数量的公告》（公告编号：2025-032）。 本议案已经公司第二届董事会薪酬与考核委员会第七次会议与 2025 年第二 次独立董事专门会议审议通过。 深圳惠泰医疗器械股份有限公司 第二届董事会第二十三 ...

Capital Change - The company increased its registered capital from RMB 97,081,956 to RMB 97,250,894 due to the first vesting of 168,938 shares from the 2021 restricted stock incentive plan on May 30, 2025 [1] - Following the 2024 annual shareholders' meeting, the company approved a profit distribution plan, resulting in a cash dividend of RMB 17.50 per 10 shares and a capital reserve increase of 4.5 shares for every 10 shares held, leading to a total share count increase to 141,013,796 and registered capital to RMB 141,013,796 [2][4] Company Charter Revision - The company plans to amend its charter to reflect the new registered capital of RMB 141,013,796 and the updated total shares issued of 141,013,796, with no changes to other charter provisions [3][4]

Core Viewpoint - The announcement details Shenzhen Huatai Medical Instrument Co., Ltd.'s decision to waive part of its preemptive rights and to increase capital in its subsidiary, Hunan Yiweidi Medical Instrument Co., Ltd., which constitutes a related party transaction [1][2][3] Summary by Sections Transaction Overview - Hunan Yiweidi is a subsidiary of Huatai Medical, with Huatai holding 42.3380% directly and controlling 68.9512% through a private equity fund [1] - The transaction involves the transfer of 10% of Yiweidi's shares and a capital increase of RMB 50 million, with RMB 1,114.8714 million allocated to registered capital and RMB 38,851,286 allocated to capital reserves [1][3] - The transaction does not constitute a major asset restructuring and has no significant legal obstacles [1][2] Related Party Transaction - The transaction was approved in meetings held on July 7, 2025, and requires shareholder approval [1][6] - The involved parties include related entities Shanghai Huishen and Shanghai Huizhen, which are linked to the company's directors and senior management [3][5] Financial Details - The overall pre-investment valuation of Yiweidi is set at RMB 130 million [5] - The financial data for related entities shows Shanghai Huishen with total assets of approximately RMB 155.5 million and net profit of RMB 240.36 million for the last fiscal year [3][4] Strategic Importance - The transaction aims to enhance Yiweidi's competitiveness and operational efficiency, aligning with Huatai's strategic focus on core business areas such as electrophysiological devices and peripheral vascular intervention products [5] - The capital increase and share transfer are designed to optimize Yiweidi's shareholder structure and governance, promoting synergy between Huatai and Yiweidi [5][6] Approval Process - The transaction has undergone a rigorous internal review process to ensure fair pricing and compliance with regulations, with related directors abstaining from voting [6][7]

General Information - The company is named Shenzhen Huitai Medical Equipment Co., Ltd. and was established through the overall change of Shenzhen Huitai Medical Equipment Co., Ltd. [2] - The company was registered with a capital of RMB 141,013,796 and is a permanent corporation [2][3] - The company was approved for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 8, 2020, and officially listed on January 7, 2021, with an initial public offering of 16.67 million shares [2] Business Objectives and Scope - The company's business objective is to focus on independent innovation and development in the field of vascular minimally invasive intervention, contributing significantly to global healthcare [2] - The business scope includes the production, operation, and leasing of various classes of medical devices, as well as technology services and development [2] Share Structure - The total number of shares issued by the company is 141,013,796, all of which are ordinary shares [3] - The company’s shares are issued in the form of stocks, and each share of the same category has equal rights [3][4] Shareholder Rights and Responsibilities - Shareholders have the right to participate in shareholder meetings, receive dividends, and request information about the company [5][6] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not abuse their rights to harm the company or other shareholders [8][9] Governance Structure - The company is governed by a board of directors, with the chairman serving as the legal representative [2][3] - The company has established an audit committee to oversee compliance and financial integrity [8] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [12][13] - Shareholders holding more than 10% of the shares can request the board to convene a temporary meeting [13][14] Financial Management - The company can increase its capital through various methods, including issuing shares to unspecified or specific targets [3][4] - The company is restricted from repurchasing its shares except under certain conditions, such as capital reduction or employee stock ownership plans [3][4] Compliance and Legal Framework - The company adheres to the Company Law and Securities Law of the People's Republic of China, ensuring that all operations are compliant with relevant regulations [2][5] - The company is required to disclose significant transactions and maintain transparency with shareholders [10][11]

Core Opinion - The audit report indicates that Hunan Yiweidi Medical Equipment Co., Ltd. has prepared its financial statements in accordance with the relevant accounting standards, providing a fair representation of its financial position as of March 31, 2025, and its operating results and cash flows for the first quarter of 2025 [1][3]. Company Overview - Hunan Yiweidi Medical Equipment Co., Ltd. was established in January 2011 and is primarily engaged in the research, development, manufacturing, and sales of medical devices, as well as the production of sanitary materials and medical supplies [3][4]. - The company is controlled by Cheng Zhenghui, who holds 42.34% of the shares [3]. Financial Reporting Basis - The financial statements are prepared based on the "Enterprise Accounting Standards" issued by the Ministry of Finance, with a focus on the going concern assumption [3][4]. - The reporting period for the financial statements is from January 1 to December 31 each year [3]. Important Accounting Policies - The company uses the Chinese Yuan (RMB) as its functional currency and recognizes cash and cash equivalents based on liquidity and risk of value change [3][4]. - Financial instruments are classified at initial recognition based on the business model and cash flow characteristics [4][5]. Financial Assets and Liabilities - Financial assets are classified into categories such as those measured at amortized cost and those measured at fair value, with specific criteria for each category [4][5]. - The company recognizes expected credit losses based on historical data and future economic forecasts, applying a probability-weighted approach [7][8]. Inventory Management - Inventory is classified into categories such as raw materials, finished goods, and work in progress, and is measured at the lower of cost or net realizable value [8][9]. Long-term Investments - Long-term equity investments are accounted for using the equity method, with adjustments made based on the investee's net income and other comprehensive income [10][11]. Fixed Assets and Depreciation - Fixed assets are recognized at cost and depreciated using the straight-line method over their useful lives, which vary by asset type [12][13]. Intangible Assets - Intangible assets are initially measured at cost, with amortization applied to those with finite useful lives [14][15]. Employee Benefits - The company recognizes short-term employee benefits as liabilities and expenses in the period they are incurred, including social insurance and housing fund contributions [18][19].